Recap: Global Payments Q2 Earnings

  Shares of Global Payments (NYSE:GPN) fell 0.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 55.73% over the past year to $2.04, which beat the estimate of $1.89.

 

Shares of Global Payments (NYSE:GPN) fell 0.0% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 55.73% over the past year to $2.04, which beat the estimate of $1.89.

Revenue of $1,941,000,000 up by 27.61% from the same period last year, which beat the estimate of $1,850,000,000.

Outlook

The upcoming fiscal year’s EPS expected to be between $8.07 and $8.20.

The upcoming fiscal year’s revenue expected to be between $7,700,000,000 and $7,730,000,000.

Conference Call Details

Date: Aug 02, 2021

Time: 08:00 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestors.globalpaymentsinc.com%2F&eventid=3192660&sessionid=1&key=0F5A2593B593AB7CA89404BC47FAE3F0&regTag=&V2=false&sourcepage=register

Technicals

Company’s 52-week high was at $220.81

52-week low: $153.33

Price action over last quarter: down 3.42%

Company Description

Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company’s shares.

Total
0
Shares
Related Posts
Read More

GE Healthcare Has Completed Recruitment In Its Phase 1 Program For A Manganese-Based Macrocyclic MRI Contrast Agent. This Manganese-Based Agent Could Provide A Potential Alternative Due To Perceived Concerns Relating To Gadolinium Retention

GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind

GEHC